Plain-English translation of NCT05460416 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether (aspirin) at a low daily dose can help prevent preeclampsia — a serious condition involving high blood pressure that can develop during pregnancy. The study will follow pregnant women who used frozen embryo transfer, giving some women the medication starting right after pregnancy is confirmed and continuing until 36 weeks of pregnancy, while others receive no treatment. Researchers will compare how many women in each group develop this condition.
Preeclampsia is a dangerous pregnancy complication that can harm both mother and baby, and women who become pregnant through frozen embryo transfer may have a higher risk. This study exists to see whether this medication, taken early and regularly, can safely prevent or reduce the chance of developing this serious condition.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to either take a 160 mg aspirin tablet daily or receive no treatment, starting as soon as your pregnancy is confirmed and continuing until 36 weeks of pregnancy. You will have regular prenatal visits twice a month, plus phone calls to check on your health. Researchers will follow you throughout your pregnancy to see if the medication helps prevent high blood pressure complications.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Belgium
Phase
Large-scale testing
Sponsor
Centre Hospitalier Universitaire de Liege
Enrollment target
~276 participants
Started
October 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 43 Years
Sex
Female only
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Julie Collée
Centre Hospitalier Régional de la Citadelle
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.